More on Biosecurity
Chairman John Moolenaar of the Select Committee on China has sent a letter to Bristol Myers Squibb Chief Executive Officer Chris Boerner asking the pharmaceutical company to provide more information about the company's clinical drug trials in China.
Chairman John Moolenaar of the Select Committee on China (SCC) has sent a letter to Eli Lilly and Company Chief Executive Officer David Ricks asking the pharmaceutical company to provide more information about the company's clinical drug trials in China.
Chairman John Moolenaar of the Select Committee on China has sent a letter to Merck Chief Executive Officer Robert Davis asking the pharmaceutical company to provide more information about the company's clinical drug trials in China.
Chairman John Moolenaar of the Select Committee on China (SCC) has sent a letter to AbbVie Chief Executive Officer Robert Michael asking the pharmaceutical company to provide more information about the company's clinical drug trials in China.
Chairman John Moolenaar of the Select Committee on China has sent a letter to Pfizer Chief Executive Officer Dr. Albert Bourla asking the pharmaceutical company to provide more information about the company's clinical drug trials in China.
WASHINGTON DC — Chairman John Moolenaar (R-MI), Ranking Member Raja Krishnamoorthi (D-IL), and Rep. Neal Dunn (R-FL) of the House Select Committee on the Chinese Communist Party wrote to Secretary of Commerce Gina Raimondo, urging the Department to update its regulations to require a license prior to engaging with a Chinese military hospital for clinical trials.
In the summer of 2024, lawmakers sought information from the FDA regarding clinical trials conducted at Chinese military hospitals, FDA site visits in the People’s Republic of China, and clinical trials occurring in Xinjiang, where the CCP is committing a genocide against the Uyghur people.
Chairman John Moolenaar (R-MI) and Ranking Member Raja Krishnamoorthi (D-IL) of the House Select Committee on the Strategic Competition Between the United States and the Chinese Communist Party joined Rep. Dan Newhouse (R-WA) and Rep. Jake Auchincloss (D-MA), co-leads of the Committee’s Fentanyl Policy Working Group, to introduce bipartisan legislation that helps hold China responsible for the fentanyl crisis.
WATCH: Lawmakers on the Select Committee' Fentanyl Policy Working Group unveil new bipartisan legislation in the working group's last meeting of the 118th Congress.
Chairman Rep. John Moolenaar's remarks, as prepared for delivery, at the final meeting of the Select Committee's Fentanyl Working Group.
Click HERE to read the full remarks.
Chairman John Moolenaar (R-MI) and Ranking Member Raja Krishnamoorthi (D-IL) of the House Select Committee on the Strategic Competition Between the United States and the Chinese Communist Party requested information from the FDA about the alarming practice of U.S. biopharmaceutical companies conducting clinical trials alongside the People’s Liberation Army (PLA) and in Xinjiang, where the CCP is engaged in genocide of the Uyghur people. Reps. Neal Dunn, M.D. (R-FL) and Anna Eshoo (D-CA) joined the inquiry, in which the lawmakers raised serious concerns that the PLA is co-opting sensitive intellectual property through these clinical trials and questioned the ethics of conducting these trials in Xinjiang.